# The Real Reason Medicine Is Unaffordable in America Source: https://www.youtube.com/watch?v=6u7iI8GhLWk Recap page: https://rapidrecap.app/video/6u7iI8GhLWk Generated: 2026-03-02T13:34:58.495+00:00 --- ## Quick Overview The unaffordability of medicine in America stems from a self-perpetuating loop involving taxpayer funding of NIH research, university patenting, pharmaceutical licensing, FDA blocking competition, and lobbying, which ultimately allows large pharmaceutical companies to maintain monopolies and charge exorbitant prices while consumers pay three times: as taxpayers, at the pharmacy, and as voters. **Key Points:** - One vial of Humalog costs $3 to manufacture but sells for a massive markup due to systemic issues, not production cost. - The price of insulin has increased by nearly 700% between 1996 and 2020, far outpacing general inflation ($35 vs $275). - The system relies on three main pillars: FDA (blocking competition), Intellectual Property Laws (granting monopolies), and Lobbying (protecting the system). - 99.4% of FDA-approved drugs between 2010 and 2019 had NIH taxpayer funding, meaning the public paid for the foundational research. - Pharmaceutical lobbying spending is massive, reaching a record $5 billion in 2025 (a 14% year-over-year increase), which protects their monopolies. - For every $100 spent on drugs, manufacturers only receive $59 in revenue; $25 goes to Pharmacy Benefit Managers (PBMs) as profit. - Alternatives like generic/biosimilar drugs exist but are suppressed because the FDA's high filing costs ($4.3 million with clinical data) and regulatory hurdles are designed to protect incumbent monopolies. ![Screenshot at 0:04: The graphic highlights that one vial of Humalog costs only $3 to manufacture in the US, setting up the contrast with the inflated prices caused by the system discussed.](https://ss.rapidrecap.app/screens/6u7iI8GhLWk/00-00-04.jpg) **Context:** The video analyzes the systemic reasons behind the high cost of essential medicines, particularly insulin, in the United States, contrasting manufacturing costs with final consumer prices. It introduces a six-part 'loop' involving government agencies, universities, and pharmaceutical companies that allegedly keeps prices artificially high and stifles competition, using examples like the discovery of insulin over a century ago to illustrate the long-term nature of the problem. ## Detailed Analysis The central argument of the video is that medicine, using insulin as a prime example, is unaffordable in America due to a systemic loop designed to protect corporate profits rather than public health. The cost to manufacture a vial of insulin is cited as merely $3, yet it sells for hundreds of dollars, an increase far exceeding general inflation over the past two decades. The speaker identifies three main pillars supporting this system: the FDA, which blocks competition by maintaining high regulatory barriers (like the $4.3 million filing fee for drugs with clinical data); Intellectual Property Laws, which grant monopolies; and lobbying, which protects the system. The video details how taxpayers fund the initial research via the NIH (99.4% of FDA-approved drugs had NIH funding between 2010-2019), universities patent the research, and pharmaceutical companies then license these patents. The FDA then blocks generic competitors, allowing the patent holder to charge monopoly prices. Furthermore, lobbying spending by big pharma and other industries (like realtors) is shown to be massive, reaching a projected $5 billion in 2025, which reinforces these protective laws. The pie chart data reveals that for every $100 spent on drugs, only $59 reaches the manufacturer, with PBMs taking $25 in profit. The speaker concludes that the solution is not more government involvement but rather dismantling these artificial constraints to allow free-market competition, which would naturally drive prices down, as seen in other industries like electronics where competition has caused prices to plummet. ### Insulin Pricing Disparity - Humalog costs $3 to manufacture vs. $300+ retail price - Insulin price increased 700% since 1996, vastly outpacing inflation. ### The System's Pillars - FDA blocks competition - Intellectual Property Laws create monopolies - Lobbying protects the system. ### Taxpayer Funding & IP Control - 99.4% of FDA-approved drugs (2010-2019) relied on NIH taxpayer funding for research - Universities patent this publicly funded research and license it to Pharma. ### Lobbying Influence - Federal lobbying spending reached a record $5 billion in 2025, with Pharma being the second-largest spender after the National Association of Realtors. ### Middlemen Profits - For every $100 spent on drugs, manufacturers receive $59, while PBMs profit $25, pharmacies $11, and wholesalers $5. ### Regulatory Barriers - FDA filing costs ($4.3M with clinical data) and patent laws prevent cheaper generic competition, thus protecting monopolies. ![Screenshot at 0:04: Graphic illustrating the massive price markup for one vial of Humalog insulin \($3 manufacturing cost vs. high retail price\).](https://ss.rapidrecap.app/screens/6u7iI8GhLWk/00-00-04.jpg) ![Screenshot at 0:48: Chart comparing the price of insulin against inflation from 1996 to 2020, showing insulin's price soaring far above general inflation.](https://ss.rapidrecap.app/screens/6u7iI8GhLWk/00-00-48.jpg) ![Screenshot at 3:46: Diagram outlining 'THE THREE MAIN PILLARS of the system' that keep medicine unaffordable: FDA, Intellectual Property Laws, and Lobbying.](https://ss.rapidrecap.app/screens/6u7iI8GhLWk/00-03-46.jpg) ![Screenshot at 7:38: Bar chart titled 'You Paid for the Research. They Own the Product,' showing 99.4% of FDA-approved drugs had NIH funding, while industry investment was significantly lower \($187B NIH vs. -$180B Industry\).](https://ss.rapidrecap.app/screens/6u7iI8GhLWk/00-07-38.jpg) ![Screenshot at 13:06: Pie chart breaking down where every $100 spent on drugs goes, showing PBMs profit $25 and manufacturers only receive $59 in revenue.](https://ss.rapidrecap.app/screens/6u7iI8GhLWk/00-13-06.jpg)